PAYSPaysign, Inc.
Paysign, Inc. (PAYS) provides patient affordability programs and payment processing solutions for the life sciences industry. The next catalyst is Nov 11, 2026 — Q3 2026 Earnings Release, which will test the company’s ability to sustain its recent revenue growth and maintain margin expansion. The event will assess the performance of its largest revenue driver, the patient affordability platform, and its progress in scaling operations.
- Revenue grew 40.5% YoY to $96.97M in the latest reported period.
- Net margin reached 20.5% in the trailing twelve months.
- Debt-to-equity ratio stands at 0.17x, reflecting a conservative capital structure.
The Read
Paysign's stock surged over 52% on Q4 2025 earnings that beat sales estimates and showed 40% revenue growth, then climbed another 29% in Q1 2026 as the patient affordability platform became its largest revenue driver, but paused briefly before rallying again on Q2 results that raised full-year guidance and highlighted expansion in key business areas.
The schedule
- Wed11Nov
The release tests whether the company can sustain its recent momentum in AI-driven financial services, with a focus on revenue growth and margin expansion. The last earnings print showed strong guidance but limited margin commentary.
- Sun14Feb
This release will test the company's ability to maintain its growth trajectory in the cloud infrastructure space, with a focus on new verticals and client diversification. The last print showed a positive surprise but limited operational detail.
- Wed12May
The release will test the company's ability to scale its AI-driven financial services and maintain its growth in the SaaS space. The last print showed a strong revenue beat but limited margin commentary.
- Thu5Aug
This release will test the company's ability to maintain its growth trajectory in the cloud infrastructure space, with a focus on new verticals and client diversification. The last print showed a positive surprise but limited operational detail.
Past
- Thu6Aug
Actual outcome: Bull
Paysign beat EPS estimates with record revenue, driven by expansion in Patient Affordability and improved plasma donor operations. The company raised full-year guidance, sending shares above the bull target despite a minor post-earnings pullback.
- Wed1Jul
Actual outcome: Bull · $8.83 at outcome
PAYS delivered positive updates regarding its expansion into new verticals and successful client diversification. The confirmation of smooth onboarding processes without delays reassured investors of the company's growth trajectory, driving shares up to the bull target.
- Wed13May
Actual outcome: Bull · $7.11 at outcome
Paysign reported its strongest start to a year in company history, with Q1 2026 revenue surging 50.8% year-over-year to $28 million and beating management guidance. The robust top-line growth and sharp margin expansion, driven by its patient affordability business becoming the largest revenue contributor, validated the operational leverage thesis and drove the stock well past the $6.70 bull target.
- Wed25Mar
Actual outcome: Bull · $5.90 at outcome
Paysign reported Q4 2025 earnings that met EPS expectations and beat sales estimates, driven by 40% revenue growth and rapid expansion in its patient affordability platform. The stock surged well past the bull target as the company's strong forward guidance and significant margin expansion signaled continued exceptional growth to investors.
